A complaint in California state court alleging OTC private label and store brand ranitidine heartburn remedies should have had label warnings for exposure to a potential carcinogenic could be the first and last Proposition 65 litigation against generic copies of nonprescription brands.
The California First Appellate District Division One has upheld a lower court’s August 2021 dismissal of a complaint filed by...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?